Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.

Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA.

Nature. 2010 Jan 21;463(7279):360-3. doi: 10.1038/nature08672. Epub 2010 Jan 6.

2.

The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.

Liao L, Testa JR, Yang H.

Cancer Genet. 2015 May;208(5):206-14. doi: 10.1016/j.cancergen.2015.02.008. Epub 2015 Feb 20. Review.

3.

BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.

Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R.

Expert Rev Mol Diagn. 2015;15(9):1201-10. doi: 10.1586/14737159.2015.1068122. Epub 2015 Jul 11. Review.

PMID:
26166446
4.

Current perspectives on histone demethylases.

Tian X, Fang J.

Acta Biochim Biophys Sin (Shanghai). 2007 Feb;39(2):81-8. Review.

5.

Examining the impact of gene variants on histone lysine methylation.

Van Rechem C, Whetstine JR.

Biochim Biophys Acta. 2014 Dec;1839(12):1463-76. doi: 10.1016/j.bbagrm.2014.05.014. Epub 2014 May 23. Review.

6.

Epigenetic regulation in RCC: opportunities for therapeutic intervention?

Larkin J, Goh XY, Vetter M, Pickering L, Swanton C.

Nat Rev Urol. 2012 Jan 17;9(3):147-55. doi: 10.1038/nrurol.2011.236. Review.

PMID:
22249190
7.

KDM5C mutational screening among males with intellectual disability suggestive of X-Linked inheritance and review of the literature.

Gonçalves TF, Gonçalves AP, Fintelman Rodrigues N, dos Santos JM, Pimentel MM, Santos-Rebouças CB.

Eur J Med Genet. 2014 Mar;57(4):138-44. doi: 10.1016/j.ejmg.2014.02.011. Epub 2014 Feb 27. Review.

PMID:
24583395
8.

Cancer genetics of epigenetic genes.

Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C.

Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R28-49. Review.

PMID:
17613546
9.

Structure and function of histone H3 lysine 9 methyltransferases and demethylases.

Krishnan S, Horowitz S, Trievel RC.

Chembiochem. 2011 Jan 24;12(2):254-63. doi: 10.1002/cbic.201000545. Epub 2011 Jan 5. Review.

10.

Roles of histone methyl-modifying enzymes in development and progression of cancer.

Suzuki T, Terashima M, Tange S, Ishimura A.

Cancer Sci. 2013 Jul;104(7):795-800. doi: 10.1111/cas.12169. Epub 2013 May 9. Review.

11.

Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination.

Ezponda T, Licht JD.

Clin Cancer Res. 2014 Oct 1;20(19):5001-8. doi: 10.1158/1078-0432.CCR-13-2499. Epub 2014 Jul 1. Review.

12.

The epigenetic landscape of renal cancer.

Morris MR, Latif F.

Nat Rev Nephrol. 2017 Jan;13(1):47-60. doi: 10.1038/nrneph.2016.168. Epub 2016 Nov 28. Review.

PMID:
27890923
13.

The H3K27me3 demethylase UTX in normal development and disease.

Van der Meulen J, Speleman F, Van Vlierberghe P.

Epigenetics. 2014 May;9(5):658-68. doi: 10.4161/epi.28298. Epub 2014 Feb 21. Review.

14.

SETD2: an epigenetic modifier with tumor suppressor functionality.

Li J, Duns G, Westers H, Sijmons R, van den Berg A, Kok K.

Oncotarget. 2016 Aug 2;7(31):50719-50734. doi: 10.18632/oncotarget.9368. Review.

15.

Oncogenic Mechanisms of Histone H3 Mutations.

Weinberg DN, Allis CD, Lu C.

Cold Spring Harb Perspect Med. 2017 Jan 3;7(1). pii: a026443. doi: 10.1101/cshperspect.a026443. Review.

PMID:
27864305

Supplemental Content

Support Center